Clinical Trial Update: ARIA (Atacand Renoprotection In NephropAthy Pt.) [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating candesartan (Atacand) for renoprotection in patients with non-diabetic nephropathy and hypertension; results were posted in 2011.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension
• Non-diabetic Nephropathy

Drugs mentioned

• Atacand (candesartan)

Snippet

Sponsor: AstraZeneca | Conditions: Non-diabetic Nephropathy With Hypertension | Phase 4 | Status: COMPLETED | Results posted: 2011-07-19